TY - JOUR T1 - <em>SERPINB11</em> Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary JF - In Vivo JO - In Vivo SP - 2647 LP - 2653 DO - 10.21873/invivo.12547 VL - 35 IS - 5 AU - SOO JIN PARK AU - WHASUN LIM AU - JAEHEE MUN AU - HAERIN PAIK AU - SUNWOO PARK AU - HYUNJI LIM AU - JUNHWAN KIM AU - EUN JI LEE AU - GA WON YIM AU - NARA LEE AU - CHEOL LEE AU - JAE-WEON KIM AU - GWONHWA SONG AU - HEE SEUNG KIM Y1 - 2021/09/01 UR - http://iv.iiarjournals.org/content/35/5/2647.abstract N2 - Background/Aim: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC). Materials and Methods: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC. Results: High expression of SERPINB11 was more common in CCC than in HGSC (57.6% vs. 28.3%; p&lt;0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of CCC was found. Conclusion: SERPINB11 expression maybe a prognostic biomarker for HGSC. ER -